Watch Demo

Pharmacovigilance Market Research Report by Type, Clinical Trial, Method, End User, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

Pharmacovigilance Market Research Report by Type, Clinical Trial, Method, End User, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030
  • Publish Date:January 2023

  • Number of Pages:126

  • Report ID:6404130

  • Format:PDF

  • Publisher:360iResearch

$ 3949

Summary

Pharmacovigilance Market Research Report by Type (Contract Outsourcing and In-house), Clinical Trial, Method, End User, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

The United States Pharmacovigilance Market size was estimated at USD 1,554.08 million in 2022 and expected to reach USD 1,772.20 million in 2023, projecting growth at a CAGR of 15.22% to reach USD 4,830.30 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Pharmacovigilance Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Pharmacovigilance Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Pharmacovigilance Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Pharmacovigilance Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Pharmacovigilance Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market is studied across Contract Outsourcing and In-house.

Based on Clinical Trial, the market is studied across Phase I, Phase II, Phase III, Phase IV, and Pre-clinical.

Based on Method, the market is studied across Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting.

Based on End User, the market is studied across Academic & Research Institutes, Government Agencies, Health Insurance Companies, Hospitals & Care Providers, and Pharma & Biotech Companies.

Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Pharmacovigilance Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Pharmacovigilance Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Pharmacovigilance Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Pharmacovigilance Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Pharmacovigilance Market, including Accenture, PLC, Bristol Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, Capgemini SE, ClinChoice Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, HCL Technologies Limited, ICON PLC, Infosys Limited, International Business Machines Corporation, IQVIA, ITclinical, Laboratory Corporation, Linical Co., Ltd., Novartis International AG, Oracle Corporation, Parexel International, Pfizer Inc., Quanticate International limited, Sanofi S.A., Take Solutions Ltd., Tata Consultancy Services, and Wipro Limited.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Pharmacovigilance Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Pharmacovigilance Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Pharmacovigilance Market?
4. What is the competitive strategic window for opportunities in the United States Pharmacovigilance Market?
5. What are the technology trends and regulatory frameworks in the United States Pharmacovigilance Market?
6. What is the market share of the leading vendors in the United States Pharmacovigilance Market?
7. What modes and strategic moves are considered suitable for entering the United States Pharmacovigilance Market?

Table of contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Pharmacovigilance Market, by Type
6.1. Introduction
6.2. Contract Outsourcing
6.3. In-house

7. Pharmacovigilance Market, by Clinical Trial
7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
7.5. Phase IV
7.6. Pre-clinical

8. Pharmacovigilance Market, by Method
8.1. Introduction
8.2. Cohort Event Monitoring
8.3. EHR Mining
8.4. Intensified ADR Reporting
8.5. Spontaneous Reporting
8.6. Targeted Spontaneous Reporting

9. Pharmacovigilance Market, by End User
9.1. Introduction
9.2. Academic & Research Institutes
9.3. Government Agencies
9.4. Health Insurance Companies
9.5. Hospitals & Care Providers
9.6. Pharma & Biotech Companies

10. California Pharmacovigilance Market
10.1. Introduction

11. Florida Pharmacovigilance Market
11.1. Introduction

12. Illinois Pharmacovigilance Market
12.1. Introduction

13. New York Pharmacovigilance Market
13.1. Introduction

14. Ohio Pharmacovigilance Market
14.1. Introduction

15. Pennsylvania Pharmacovigilance Market
15.1. Introduction

16. Texas Pharmacovigilance Market
16.1. Introduction

17. Competitive Landscape
17.1. FPNV Positioning Matrix
17.1.1. Quadrants
17.1.2. Business Strategy
17.1.3. Product Satisfaction
17.2. Market Ranking Analysis, By Key Player
17.3. Market Share Analysis, By Key Player
17.4. Product Portfolio Analysis, By Key Player
17.5. Competitive Scenario
17.5.1. Merger & Acquisition
17.5.2. Agreement, Collaboration, & Partnership
17.5.3. New Product Launch & Enhancement
17.5.4. Investment & Funding
17.5.5. Award, Recognition, & Expansion

18. Company Usability Profiles
18.1. Accenture, PLC
18.2. Bristol Myers Squibb
18.3. C.H. Boehringer Sohn AG & Ko. KG
18.4. Capgemini SE
18.5. ClinChoice Inc.
18.6. F. Hoffmann-La Roche AG
18.7. GlaxoSmithKline PLC
18.8. HCL Technologies Limited
18.9. ICON PLC
18.10. Infosys Limited
18.11. International Business Machines Corporation
18.12. IQVIA
18.13. ITclinical
18.14. Laboratory Corporation
18.15. Linical Co., Ltd.
18.16. Novartis International AG
18.17. Oracle Corporation
18.18. Parexel International
18.19. Pfizer Inc.
18.20. Quanticate International limited
18.21. Sanofi S.A.
18.22. Take Solutions Ltd.
18.23. Tata Consultancy Services
18.24. Wipro Limited

19. Appendix
19.1. Discussion Guide
19.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES PHARMACOVIGILANCE MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES PHARMACOVIGILANCE MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES PHARMACOVIGILANCE MARKET DYNAMICS
FIGURE 8. UNITED STATES PHARMACOVIGILANCE MARKET PORTER'S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES PHARMACOVIGILANCE MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2030
FIGURE 12. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CONTRACT OUTSOURCING, 2018-2030 (USD MILLION)
FIGURE 13. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
FIGURE 14. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2022 VS 2030 (%)
FIGURE 15. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES PHARMACOVIGILANCE MARKET COMPETITIVE STRATEGIC WINDOW, BY CLINICAL TRIAL, 2030
FIGURE 17. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, 2018-2030 (USD MILLION)
FIGURE 18. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, 2018-2030 (USD MILLION)
FIGURE 19. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, 2018-2030 (USD MILLION)
FIGURE 20. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, 2018-2030 (USD MILLION)
FIGURE 21. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, 2018-2030 (USD MILLION)
FIGURE 22. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2022 VS 2030 (%)
FIGURE 23. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES PHARMACOVIGILANCE MARKET COMPETITIVE STRATEGIC WINDOW, BY METHOD, 2030
FIGURE 25. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, 2018-2030 (USD MILLION)
FIGURE 26. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, 2018-2030 (USD MILLION)
FIGURE 27. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, 2018-2030 (USD MILLION)
FIGURE 28. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, 2018-2030 (USD MILLION)
FIGURE 29. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, 2018-2030 (USD MILLION)
FIGURE 30. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 31. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 32. UNITED STATES PHARMACOVIGILANCE MARKET COMPETITIVE STRATEGIC WINDOW, BY END USER, 2030
FIGURE 33. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
FIGURE 34. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
FIGURE 35. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY HEALTH INSURANCE COMPANIES, 2018-2030 (USD MILLION)
FIGURE 36. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, 2018-2030 (USD MILLION)
FIGURE 37. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, 2018-2030 (USD MILLION)
FIGURE 38. CALIFORNIA PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 39. FLORIDA PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 40. ILLINOIS PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 41. NEW YORK PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 42. OHIO PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 43. PENNSYLVANIA PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 44. TEXAS PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 45. UNITED STATES PHARMACOVIGILANCE MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 46. UNITED STATES PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 47. UNITED STATES PHARMACOVIGILANCE MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

List of Tables

TABLE 1. UNITED STATES PHARMACOVIGILANCE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 5. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CONTRACT OUTSOURCING, 2018-2030 (USD MILLION)
TABLE 7. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CONTRACT OUTSOURCING, BY STATE, 2018-2030 (USD MILLION)
TABLE 8. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 9. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY STATE, 2018-2030 (USD MILLION)
TABLE 10. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 11. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, 2018-2030 (USD MILLION)
TABLE 12. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY STATE, 2018-2030 (USD MILLION)
TABLE 13. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, 2018-2030 (USD MILLION)
TABLE 14. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY STATE, 2018-2030 (USD MILLION)
TABLE 15. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, 2018-2030 (USD MILLION)
TABLE 16. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY STATE, 2018-2030 (USD MILLION)
TABLE 17. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, 2018-2030 (USD MILLION)
TABLE 18. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY STATE, 2018-2030 (USD MILLION)
TABLE 19. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, 2018-2030 (USD MILLION)
TABLE 20. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY STATE, 2018-2030 (USD MILLION)
TABLE 21. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY STATE, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY STATE, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY STATE, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY STATE, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY STATE, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY STATE, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY GOVERNMENT AGENCIES, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY HEALTH INSURANCE COMPANIES, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY HEALTH INSURANCE COMPANIES, BY STATE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY STATE, 2018-2030 (USD MILLION)
TABLE 43. CALIFORNIA PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 44. CALIFORNIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. CALIFORNIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 46. CALIFORNIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 47. CALIFORNIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. FLORIDA PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 49. FLORIDA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. FLORIDA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 51. FLORIDA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 52. FLORIDA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. ILLINOIS PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 54. ILLINOIS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. ILLINOIS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 56. ILLINOIS PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 57. ILLINOIS PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. NEW YORK PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 59. NEW YORK PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 60. NEW YORK PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 61. NEW YORK PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 62. NEW YORK PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. OHIO PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 64. OHIO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. OHIO PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 66. OHIO PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 67. OHIO PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. PENNSYLVANIA PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 69. PENNSYLVANIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. PENNSYLVANIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 71. PENNSYLVANIA PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 72. PENNSYLVANIA PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. TEXAS PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 74. TEXAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. TEXAS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 76. TEXAS PHARMACOVIGILANCE MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 77. TEXAS PHARMACOVIGILANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES PHARMACOVIGILANCE MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 79. UNITED STATES PHARMACOVIGILANCE MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 80. UNITED STATES PHARMACOVIGILANCE MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 81. UNITED STATES PHARMACOVIGILANCE MARKET RANKING, BY KEY PLAYER, 2022
TABLE 82. UNITED STATES PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2022
TABLE 83. UNITED STATES PHARMACOVIGILANCE MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 84. UNITED STATES PHARMACOVIGILANCE MARKET MERGER & ACQUISITION
TABLE 85. UNITED STATES PHARMACOVIGILANCE MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 86. UNITED STATES PHARMACOVIGILANCE MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 87. UNITED STATES PHARMACOVIGILANCE MARKET INVESTMENT & FUNDING
TABLE 88. UNITED STATES PHARMACOVIGILANCE MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 89. UNITED STATES PHARMACOVIGILANCE MARKET: LICENSE & PRICING

Companies Mentioned

Accenture, PLC
Bristol Myers Squibb
C.H. Boehringer Sohn AG & Ko. KG
Capgemini SE
ClinChoice Inc.
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
HCL Technologies Limited
ICON PLC
Infosys Limited
International Business Machines Corporation
IQVIA
ITclinical
Laboratory Corporation
Linical Co., Ltd.
Novartis International AG
Oracle Corporation
Parexel International
Pfizer Inc.
Quanticate International limited
Sanofi S.A.
Take Solutions Ltd.
Tata Consultancy Services
Wipro Limited

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.